Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Mol Cancer Res. 2017 Nov 13;16(2):296–308. doi: 10.1158/1541-7786.MCR-17-0308

Figure 1. CCR2 overexpression in SUM225 breast cancer cells enhances invasive progression.

Figure 1

A. Flow cytometry analysis for CCR2 expression in parental DCIS.com or SUM225 parental cells or SUM225 cells expressing vehicle pHAGE control or CCR2 (CCR2-L, CCR2-H). Histogram analysis shown on left. Graph shows percentages of positive cells. B. Tissue mass of SUM225 MIND injected mammary glands C. SUM225 lesions were co-stained for CK-19 (red) and α-sma (green), and scored for the number of invasive lesions n=252 lesions for control pHAGE, 272 lesions for CCR2-L, and 231 for CCR2-H group. Representative images are shown with secondary antibody control panel of anti-rabbit-Alexa-fluor488/anti-mouse-Alexa-fluor-568/DAPI overlay. Arrows indicate invasive foci. D-E. Image J quantification of immunostaining for Ki67 (D) or cleaved caspase-3 (E) in SUM225 lesions (arbitrary units). Arrows point to examples of positive staining. Statistical analysis was performed using One way ANOVA with Bonferonni post-hoc comparison (B, D, E) or Chi square test (C). Statistical significance was determined by p<0.05. *p<0.05. ns= not significant. Mean±SEM values are shown. Scale bar=200 microns.